YMTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 12.45%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Yumanity Therapeutics Insider Trading History Chart

Yumanity Therapeutics Share Price & Price History

^$0.00

+0.30 (1.20%)

As of 10/24/2024 01:00 AM ET

⭕ [URGENT] Buy Alert just triggered

From Behind the Markets | Ad

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

Yumanity Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/2/2022	Michael D Wyzga	Insider	Sell	3,116	$1.69	$5,266.04	13,997
12/2/2022	Richard Peters	CEO	Sell	10,890	$1.69	$18,404.10	90,028
7/5/2022	Richard Peters	CEO	Sell	4,584	$1.85	$8,480.40	100,918
6/3/2022	Devin Whittemore Smith	SVP	Sell	2,923	$1.19	$3,478.37	17,077
6/3/2022	Marie Epstein	Insider	Sell	1,806	$1.19	$2,149.14	10,859
6/3/2022	Richard Peters	CEO	Sell	10,206	$1.19	$12,145.14	105,502
3/28/2022	Richard Peters	CEO	Sell	10,715	$1.85	$19,822.75
2/3/2022	Paulash Mohsen	Insider	Sell	1,958	$1.83	$3,583.14

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis

From Stansberry Research | Ad

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.

SEC Filings (Institutional Ownership Changes) for Yumanity Therapeutics (NASDAQ:YMTX)

25.10% of Yumanity Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Yumanity Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/12/2022	Ikarian Capital LLC	104,392	$0.19M	0.0%	-55.8%	0.962%
8/1/2022	Monaco Asset Management SAM	50,000	$91K	0.0%	N/A	0.461%
2/10/2022	Acadian Asset Management LLC	75,928	$0.22M	0.0%	+272.7%	0.737%
11/17/2021	Altium Capital Management LP	196,000	$2.02M	0.5%	+58.5%	1.902%
11/16/2021	Bain Capital Public Equity Management II LLC	27,972	$0.29M	0.0%	-8.3%	0.271%
11/15/2021	Sphera Funds Management LTD.	75,836	$0.78M	0.1%	-34.2%	0.736%
11/15/2021	Ovata Capital Management Ltd	18,700	$0.19M	0.1%	N/A	0.181%
11/15/2021	Ensign Peak Advisors Inc	33,840	$0.35M	0.0%	N/A	0.328%
11/12/2021	Renaissance Technologies LLC	35,919	$0.37M	0.0%	N/A	0.349%
11/12/2021	Stonepine Capital Management LLC	481,692	$4.97M	2.3%	+9.0%	4.674%
11/12/2021	Jump Financial LLC	10,300	$0.11M	0.0%	N/A	0.100%
11/9/2021	BlackRock Inc.	69,905	$0.72M	0.0%	+6.9%	0.678%
8/17/2021	Sphera Funds Management LTD.	115,298	$1.34M	0.1%	-44.7%	1.130%
8/17/2021	Boothbay Fund Management LLC	304,475	$0.17M	0.0%	+2,000.1%	2.984%
8/16/2021	Redmile Group LLC	59,487	$0.69M	0.0%	-90.3%	0.583%
8/16/2021	Diametric Capital LP	20,939	$0.24M	0.2%	N/A	0.205%
8/13/2021	Altium Capital Management LP	123,693	$1.44M	0.3%	+13.8%	1.212%
8/13/2021	Geode Capital Management LLC	21,024	$0.24M	0.0%	+16.1%	0.206%
8/5/2021	GSA Capital Partners LLP	10,369	$0.12M	0.0%	N/A	0.102%
5/21/2021	Citadel Advisors LLC	47,381	$43K	0.0%	N/A	1.816%
5/18/2021	Citadel Advisors LLC	47,381	$43K	0.0%	N/A	0.000%
5/17/2021	Sphera Funds Management LTD.	208,609	$3.78M	0.3%	+59.9%	0.000%
5/17/2021	Ikarian Capital LLC	219,470	$3.97M	0.1%	+65.6%	0.000%
5/12/2021	Geode Capital Management LLC	18,108	$0.33M	0.0%	+9.6%	0.000%
5/12/2021	Pura Vida Investments LLC	68,853	$1.25M	0.0%	N/A	0.000%
5/7/2021	BlackRock Inc.	64,431	$1.17M	0.0%	+18.3%	0.000%
2/16/2021	HarbourVest Partners LLC	22,030	$0.38M	0.1%	N/A	0.000%
2/12/2021	Stonepine Capital Management LLC	108,847	$1.85M	1.4%	N/A	0.000%
2/12/2021	Ikarian Capital LLC	132,514	$2.25M	0.1%	N/A	0.000%
2/11/2021	Artal Group S.A.	217,391	$3.70M	0.1%	N/A	0.000%
2/10/2021	Renaissance Technologies LLC	18,349	$0.31M	0.0%	N/A	0.000%
2/9/2021	Wells Fargo & Company MN	2,898	$50K	0.0%	N/A	0.000%
2/5/2021	BlackRock Inc.	54,469	$0.93M	0.0%	N/A	0.000%

Data available starting January 2016

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.